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Erythropoietin (EPO) is a neuroprotective cytokine, which has been applied in several
animal models presenting neurological disorders. One of the proposed modes of action
resulting in neuroprotection is post-transcriptional gene expression regulation.This directly
brings to mind microRNAs (miRNAs), which are small non-coding RNAs that regulate gene
expression at the post-transcriptional level. It has not yet been evaluated whether miRNAs
participate in the biological effects of EPO or whether it, inversely, modulates specific miR-
NAs in neuronal cells. In this study, we employed miRNA and mRNA arrays to identify how
EPO exerts its biological function. Notably, miR-451 and miR-885-5p are downregulated in
EPO-treated SH-SY5Y neuronal-like cells. Accordingly, target prediction and transcriptome
analysis of cells treated with EPO revealed an alteration of the expression of genes involved
in apoptosis, cell survival, proliferation, and migration. Low expression of miRNAs in SH-
SY5Y was correlated with high expression of their target genes, vascular endothelial growth
factor A, matrix metallo peptidase 9 (MMP9), cyclin-dependent kinase 2 (CDK2), erythro-
poietin receptor, Mini chromosome maintenance complex 5 (MCM5), B-cell lymphoma
2 (BCL2), and Galanin (GAL). Cell viability, apoptosis, proliferation, and migration assays
were carried out for functional analysis after transfection with miRNA mimics, which inhib-
ited some biological actions of EPO such as neuroprotection, anti-oxidation, anti-apoptosis,
and migratory effects. In this study, we report for the first time that EPO downregulates
the expression of miRNAs (miR-451 and miR-885-5p) in SH-SY5Y neuronal-like cells. The
correlation between the over-expression of miRNAs and the decrease in EPO-mediated bio-
logical effects suggests that miR-451 and miR-885-5p may play a key role in the mediation
of biological function.
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INTRODUCTION
Erythropoietin (EPO) is a hematopoietic cytokine that regulates
erythropoiesis (1). Its primary production sites are the fetal liver
and the adult kidney. Nonetheless, EPO is also produced by many
non-hematopoietic tissues including the central nervous system
(CNS). It has now been well established that different cell types
of the CNS (neurons, glial cells, and endothelial cells) produce
EPO (2). In addition to producing EPO, these cells also express the
erythropoietin receptor (EPOR) on their plasma membranes thus
underlining the crucial role that EPO plays in the physiological
function of these cells (3).
Recombinant human erythropoietin (rhEPO) is a well-known
FDA approved drug that has been used for the treatment of chronic
anemia associated with renal failure, cancer, and prematurity since
1989 (1). It has been shown that EPO can cross the blood–brain
barrier (BBB) via a receptor-mediated mechanism (4). EPO exerts
remarkable neuroprotection for both, in vitro and in vivo models
of nervous system disorders. In vitro studies showed that EPO is
directly neuroprotective in hypoxic, hypoglycemic, and excitotoxic
neuronal injury models (5). Exogenous administration of rhEPO
protects the brain against neurodegeneration in a wide variety
of experimental neurological disorders including stroke, neonatal
hypoxic–ischemic encephalopathy, multiple sclerosis (MS), sub-
arachnoid hemorrhage, traumatic brain injury, epileptic seizure,
Parkinson’s disease (PD), Alzheimer’s disease (AD), and spinal
cord injury (2, 6). EPO is currently being under investigation in
several clinical trials regarding neuropsychiatric diseases (6).
Erythropoietin protects the CNS cells by limiting the produc-
tion of tissue-injuring molecules such as reactive oxygen species
(ROS) and glutamate, attenuation of apoptosis, modulation of
inflammation, stimulation of angiogenesis, and induction of neu-
rogenesis (7). However, the tissue-protective mechanisms of EPO
are still not fully understood. EPO’s impact on regulation at both
the transcriptional and the post-transcriptional levels may play a
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critical role for its cellular effects. EPO activates various signal-
ing pathways that result in gene expression changes responsible
for its biological activities (8). Previous in vitro (9) and in vivo
(10–14) studies using mRNA microarrays evaluated genome-wide
expression changes induced by EPO.
Some genes regulated by EPO may host microRNAs (miR-
NAs), which are then automatically regulated as well. This is then
further propagated to the miRNA targets whose transcriptions
generally increase with downregulation of its associated miRNAs.
miRNAs are short, single stranded, RNA molecules that regu-
late gene expression at the post-transcriptional level (15). Since
their discovery about two decades ago (16), they have spawned
a great amount of interest and, thus the modulation of gene
expression by miRNAs has been highly investigated. These small
RNA molecules generally downregulate gene expression usually
by binding to complementary sequences in their target mRNAs’
3′ untranslated region. miRNAs are likely to be involved in most
biological processes including development, cell cycle, apoptosis,
proliferation, and angiogenesis (15). They have been demon-
strated to be essential for brain development and function, and
to influence the neuropsychiatric diseases (17). Therefore, it is
reasonable to hypothesize that some miRNAs play roles in EPO-
related neuroprotective mechanisms in neuronal cells. To date,
there is only one study that indicates the importance of miRNAs
for the biological effects of EPO on erythropoiesis (18). However,
there is currently no study that demonstrates the contribution
of miRNAs to the EPO-mediated neuroprotective mechanisms in
neuronal cells.
The aim of this study is to determine global expression changes
of miRNAs induced by EPO in vitro and the role of specific miR-
NAs in biological function of EPO in SH-SY5Y neuron-like cells.
To achieve this, we have identified specific miRNAs via microar-
ray analysis whose transcriptional levels were further validated
by quantitative PCR (qPCR). EPO caused changes in the expres-
sion of specific miRNAs and their target genes involved in cell
proliferation, migration, cell survival, and redox regulation. More-
over, these results were confirmed with functional studies by using
miRNA mimics. Our results provide a new molecular insight
into the cellular and molecular mechanism of EPO action in
neuronal cells.
MATERIALS AND METHODS
CELL CULTURE AND TREATMENT
SH-SY5Y cells were maintained in Dulbecco’s Modified Eagle
Medium: nutrient mixture F-12 (DMEM:F12) (Gibco, Gaithers-
burg, MD, USA) supplemented with heat-inactivated fetal
bovine serum (10% v/v), l-glutamine (1% v/v), and penicillin-
streptomycin (1% v/v) at 37°C in 5% CO2.
Twenty-four hours after initial plating of the SH-SY5Y cells,
EPO was added at 1 U/ml concentration. Samples were collected
after 24 h for quantification of miRNAs expression.
MicroRNA EXTRACTION AND MICROARRAY SCREENING
Total RNA was isolated from EPO-treated and -untreated cells
using the miRNeasy kit (Qiagen GmbH, Hilden) according to the
manufacturer’s protocol. Microarray studies were carried out by
FEBIT Company as described before (19). Samples were analyzed
with a Geniom Real time Analyzer (GRTA, FEBIT GmbH, Hei-
delberg, Germany) using the Geniom miRNA Homo sapiens
Biochip. Every array included 710 miRNAs and miRNA star
sequences (seven replicates) which are annotated in the Sanger
miRBase 20.0. The labeling of samples with biotin was performed
by microfluidic-based enzymatic on-chip labeling of miRNAs.
Hybridization was carried out for 16 h at 42°C, and the biochip
was washed automatically. The image data were analyzed with
the Geniom Wizard Software. The analyses included data back-
ground correction, normalization, and determination of differen-
tially expressed miRNAs. Background correction was performed
by subtracting the median of blank controls from median of each
spots. Quantile normalization and variance stabilizing normal-
ization were applied for normalization of the data across different
arrays. The significant differentially expressed miRNAs were deter-
mined by an adjusted p value lower than 0.05 based on the multiple
testing using the Benjamini–Hochberg procedures (20, 21).
REAL-TIME PCR ANALYSIS OF miR-451 AND miR-885-5p
Quantitative PCR assay was used to confirm the miRNAs (miR-
451 and miR-885-5p) that were found to be differentially regulated
in the microarray experiment. Total RNA was isolated from cells
using Qiagen miRNeasy Mini Kit and RNA quantity was measured
with the NanoDrop Spectrophotometer (Thermo Scientific, USA).
Then, 2µg RNA was reverse-transcribed with a specific stem-loop
primer using miScript II RT Kit (Qiagen,Valencia, CA, USA). Real-
time PCR was performed using miScript SYBR Green PCR Kit
on a Lightcycler 1.5 Real-Time PCR System (Roche Diagnostics,
Germany). Primers for mature miR-451, miR-885-5p SNORD95,
and U6 were purchased from Qiagen (Valencia, CA, USA). The
PCR reactions were performed at 95°C for 10 min, followed by
40 cycles at 95°C for 15 s and at 60°C for 30 s. The specificity
of the PCR products was analyzed by the melting curve analysis.
The relative expression levels of miRNAs were normalized to the
average amounts of U6 and SNORD95 snRNA using the 2−∆∆Ct
formulation (22).
MicroRNA TARGET PREDICTION
miRWalk online prediction software1 was used for searching the
validated and predicted targets of the altered miRNAs. miR-
Walk combines nine established target prediction tools: miR-
Walk, Diana-microT, miRanda, miRDB, PICTAR), PITA, RNA22,
RNAhybrid, and Targetscan. Target prediction was performed sep-
arately for miR-451 and miR-885-5p with a p value <0.05. To
establish the interaction network of the miRNAs with the Reac-
tome2 pathways, only targets found in miRTarBase3 and Tarbase4
were accepted since they have experimental evidence.
mRNA ARRAY
Microarray analysis was performed by Aros Applied Biotechnol-
ogy (Denmark) using with the Human-6 v2 Expression BeadChip
(Illumina Inc., San Diego, CA, USA). Briefly, total RNA isolated
1http://www.umm.uni-heidelberg.de/apps/zmf/mirwalk/
2http://www.reactome.org/
3http://mirtarbase.mbc.nctu.edu.tw/
4http://diana.imis.athena-innovation.gr/DianaTools/index.php?r=tarbase/index
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from SH-SY5Y cells treated with or without EPO, by using Qiagen
miRNeasy Mini Kit. cDNA was synthesized from 500 ng total
RNA, and then hybridized onto an Illumina Beadchip for 16 h
at 58°C, then washed, stained, and scanned. Variance stabilization
was performed using variance stabilization transformation and
the data were normalized by quantile normalization. All the Illu-
mina IDs (probes) were assumed to be differentially expressed if
their ANOVA values were ≤0.5. All experiments were performed
in triplicate and overall >98% correlation was observed between
replicates.
REAL-TIME qPCR ARRAY
Real-time qPCR array analysis was performed by Aros Applied
Biotechnology (Denmark) using same RNA samples in microar-
ray experiments for 26 differentially regulated genes in microarray
analysis. Briefly, total RNA isolated from SH-SY5Y cells treated
with or without EPO, by using Qiagen miRNeasy Mini Kit. cDNA
was synthesized from 500 ng total RNA, then real-time PCR array
analysis was performed in a total volume of 20µl including 2µl
of cDNA, primers, and 10µl of SYBR Green mix. Reactions were
run on a Light cycler 480 using the universal thermal cycling para-
meters. Expression of target mRNA was normalized with respect
to actin using the 2−∆∆Ct method.
REAL-TIME PCR ANALYSIS OF mRNAs
Total RNA was isolated using the Nucleospin RNA II Kit
(Macherey-Nagel, Germany) and converted to cDNA with
RevertAid First Strand cDNA Synthesis Kit (Thermo Fermentas,
ABD). Real-time qPCR was performed using the Lightcycler 1.5
Instrument (Roche, ABD) and the SYBR-Green I kit, following
the manufacturer’s instructions. The primers used in the qPCR
reactions are listed in Table 1. PCR amplification of the tem-
plate cDNAs were performed using following conditions for 40
cycles. After initial denaturation at 95°C for 10 min, temperature
cycling of denaturation at 95°C for 10 s, annealing at 60°C for
10 s, and extension at 72°C for 20 s was performed. The specificity
of the PCR products was analyzed by the melting curve analysis.
The relative expression levels of mRNAs were quantified using the
2−∆∆ Ct method with endogenous normalization to the average
amounts of glyceraldehyde 3-phosphate dehydrogenase (GAPDH )
and ribosomal protein, large, P0 (RPLP0).
WST-8 ASSAY
Cell viability was assessed by the ability of viable cells to reduce
WST-8 reagent [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-
5-(2,4-disulfophenyl)-2H-tetrazolium, monosodium salt] to the
highly water soluble formazan dye. Cells were seeded in 96-well
plate at a density of 2× 104 cells per well. After treatment with
EPO and/or a toxic agent, 10µl of WST-8 reagent was added to
each well containing 100µl of medium. The plate was then incu-
bated for 4 h at 37°C and the absorbance of each well was measured
on a microplate reader (Biotek, USA) at 450 nm with a reference
wavelength of 630 nm. The relative cell viability was calculated as
the percentage of untreated cells.
TRYPAN BLUE STAINING
Cell viability was also evaluated by trypan blue dye exclusion.
Cells were seeded on a 24-well plate at a density of 5× 105 cells
Table 1 | Primer sequences for RT-qPCR.
Gene Primer sequences
GAPDH Forward 5′-ACCACAGTCCATGCCATCAC-3′
Reverse 5′-TCCACCACCCTGTTGCTGTA-3′
RPLP0 Forward 5′-GCATCAGTACCCCATTCTATCA-3′
Reverse 5′-AAGGTGTAATCCGTCTCCACAGA-3′
BCL2 Forward 5′-CTGGTGGACAACATCGCTCTG-3′
Reverse 5′-GGTCTGCTGACCTCACTTGTG-3′
VEGFA Forward 5′-TGGTTGCCCTTTTCTACTTTG-3′
Reverse 5′-GAAGTAGGAAAGGAGGCCATC-3′
CDK2 Forward 5′-ACCACAGTCCATGCCATCAC-3′
Reverse 5′-TCCACCACCCTGTTGCTGTA-3′
MMP9 Forward 5′-GACCATAGAGGTGCCGGATG-3′
Reverse 5′-GGACAAGCTCTTCGGCTTCT-3′
MCM5 Forward 5′-AGCAGAAATACCCGGAGCAC-3′
Reverse 5′-AACGGATGCCAAAAGCACAC-3′
EPOR Forward 5′-CAATGAAGTAGTGCTCCTAGACG-3′
Reverse 5′-TCCAGCACCAGATAGGTATCC-3′
GAL Forward 5′-CGCAGCTCAAGGTACTACTG-3′
Reverse 5′-GGGGCTGTTGATACACTCGG-3′
per well. Following incubation, cells were stained with trypan blue
stain for 1 min and fixed with 2% paraformaldehyde for 20 min.
Stained cells were photographed by using an inverted microscope
(Olympus CKX41, Japan).
DNA FRAGMENTATION ASSAY
The Cell Death Detection ELISA Kit was used to evaluate DNA
fragmentation in the cytoplasm of apoptotic cells. SH-SY5Y cells
were seeded in a 96-well plate at a density of 2× 104 cells per well.
SH-SY5Y cells were pretreated with EPO (1 U/ml) for 24 h. Then
toxic agents were added to the cell culture medium. Staurosporine
(STS) was used at a concentration of 25 nM for 6 h; CoCl2 was
used at a concentration of 250µM for 24 h. Following treatment,
cells were incubated in the lysis buffer for 30 min. Thereafter, the
samples were centrifuged at 200×g for 10 min and 20µl of the
supernatant was transferred to a streptavidin coated microplate.
Then the HRP-conjugated antibody cocktail was added to each
well. After 2 h of incubation at room temperature, ABTS (2,2-
azino-di-3-ethylbenzthiazoline sulfonate) was added to the wells.
Subsequent to 15-min incubation, the plates were read at a wave-
length of 405 nm in a microplate reader. The results are represented
as fold increase in respect to optical density as compared with
control cells.
ANNEXIN-V IMMUNOSTAINING
Annexin-V-FITC apoptosis detection kit I (Becton Dickinson,
USA) was used to detect apoptotic cells. At the end of incuba-
tion, cells were stained with Annexin-V according to the manu-
facturer’s instructions. After staining procedure, cells were fixed
with 4% paraformaldehyde for 20 min. Stained cells were pho-
tographed by using a fluorescence microscope (Olympus BX50,
Japan).
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CELL PROLIFERATION ASSAY
SH-SY5Y cells were seeded in a 24-well plate at a density of
75× 103 cells per well and treated with or without EPO. After
24 h of EPO treatment, cell culture plates were first washed three
times with PBS, the cells then harvested by trypsinization and the
cell number was determined using a hemocytometer.
INTRACELLULAR ROS QUANTIFICATION
Intracellular ROS quantification was measured by 2′,7′-
dichlorodihydrofluorescein, acetyl ester (CM-H2DCFDA) (Invit-
rogen). Cells were seeded into black 96-well plate at 2× 104
cells per well and were treated with EPO for 24 h. Then, 100µl
PBS containing 10µM CM-H2DCFDA was added to each well
and incubated for 1 h. Afterward, CM-H2DCFDA was removed
from each well and cells were treated with CoCl2 (250µM) or
both CoCl2 (250µM) and EPO for 24 h. Fluorescence levels were
determined following excitation with a wavelength of 492 nm at
an emission wavelength of 527 nm by using a microplate reader
(BioTek, USA).
MIGRATION ASSAY
The SH-SY5Y cells were seeded at a density of 2× 105 cells/well
in 24-well plates, and incubated in DMEM/F12 containing 10%
FBS for 24 h to confluence. A confluent monolayer of each well
was scratched with a 200µl pipette tip and cells were washed
twice with PBS and replaced with fresh growth medium contain-
ing 1% FBS, with or without EPO. Immediately after the scratch
(0 h) and at 24 h, four wounded area were marked in each well
and images obtained using phase-contrast inverted microscope
(Olympus, CKX41; 10×). The same wounded area was selected
for the measurements at each time of study. The number of cells
that migrated over the margins of the wounds was counted by
using ImageJ 1.425. All experiments were performed in triplicate,
and each experiment was repeated at least three times.
NEURIT OUTGROWTH AND COUNT
SH-SY5Y cells were transfected with miR-451 and miR-885-5p
mimics and negative control oligomers as described before (Qia-
gen, USA). After transfection, cells were treated with 1 U/ml Epo
for 24 h, then, cells were photographed by using an inverted micro-
scope (Eclipse TS120, Nikon) using phase-contrast objectives with
a 40×magnification.
For quantifying the number of neurites per cell, neurite-
bearing cells were counted from at least three randomly selected
microscopic fields with an average of 35 cells per field.
Additionally, neurite length was measured from all neurite-
bearing cells and the length of each neurite was quantified by
using ImageJ 1.425. Neurite lengths that counted from three differ-
ent images and at least 30 neurites per condition were quantified.
Independent cell culture experiments were conducted in triplicate.
TRANSFECTION OF miRNAs MIMICS
MicroRNA mimics and negative controls were purchased from
Qiagen. SH-SY5Y cells were transfected 24 h after seeding in cell
5http://imagej.nih.gov/ij/
culture plates. Transfection of cells with miR-451 and miR-885-5p
mimics and negative control oligomers (Qiagen) was performed
using the HiPerFect transfection reagent (Qiagen) according to
the manufacturer’s protocol. The final concentration of the mim-
ics was 50 nM. Samples were collected after 48 h of miRNA
mimic transfections for quantification of miRNA and target gene
expression.
STATISTICAL ANALYSIS
Statistical analyses were performed with SPSS 18.0. Values repre-
sent the average± SEM. Differences among averages were analyzed
by Student’s t -test or Mann–Whitney U test. p values smaller
than 0.05 were considered to be statistically significant. The cor-
relation between the results of mRNA array and qPCR array was
investigated by Pearson’s correlation analysis test.
RESULTS
PROFILING microRNA EXPRESSION CHANGES FOLLOWING EPO
TREATMENT
MicroRNA microarrays were used to identify miRNAs with altered
expression due to treatment with EPO. SH-SY5Y cells were treated
with 1 U/ml EPO for 24 h. Analysis of the microRNA expression
using microRNA arrays showed that miR-451 and miR-885-5p
expression decreased in response to treatment with EPO in SHSY-
5Y cells according to the criteria of a fold change ≤−1.5 or ≥1.5
(P< 0.05) (Table S1 in Supplementary Material).
These results were validated by quantitative qPCR, using miR-
451 and miR-885-5p specific primers, which recognize their
mature forms. Consistent with the microarray results, both miR-
451 and miR-885-5p were downregulated following 24 h of treat-
ment with EPO (Figures 1A,B). In addition, 48 h EPO treatment
also decreases expression of miR-451 and miR-885-5p in SH-SY5Y
cells (Figures 1A,B).
TARGET GENE PREDICTION
To search the validated and predicted targets for differentially
expressed miRNAs miRWalk software1 was used. An mRNA was
considered a potential target if it appeared in at least three of
the algorithms utilized. Employing that criterion, we obtained
1831 predicted and 117 validated target genes for miR-451 and
miR-885-5p.
MiRTarBase (23) and TarBase (24) are two databases, which
contain miRNA targets with the restriction that each target
must have experimental evidence. We therefore used these two
databases to determine the targets for construction of a regu-
latory network intersected with Reactome pathways (25). miR-
451 has Anti-Müllerian hormone (AMH ), Calcium-binding pro-
tein 39 (CAB39), ATP-binding cassette sub-family B member 1
(ABCB1), AKT1, IMP2 inner mitochondrial membrane peptidase-
like (IMMP2L), B-cell lymphoma 2 (BCL2), cAMP-regulated
phosphoprotein 19 (ARPP19), Fructose-1,6-bisphosphatase 1
(FBP1), matrix metallopeptidase 9 (MMP9), myc, transmem-
brane emp24 protein transport domain containing 7 (TMED7 ),
and ubiquitin-conjugating enzyme E2H (UBE2H ) as confirmed
targets. miR-885-5p has the experimentally supported targets
cyclin-dependent kinase 2 (CDK2), and minichromosome main-
tenance complex component 5 (MCM5). While miR-451 is part of
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FIGURE 1 | Erythropoietin decreases miR-451 and miR-885-5p expression in SH-SY5Y cells. Cells were treated with 1 U/ml EPO during 24 and 48 h.
Expression levels of miR-451 (A) and miR-885-5p (B) in both treated and non-treated cells were quantified by qRT-PCR. EPO; erythropoietin. The data are
presented as mean±SE, n= 5 (*p<0.05).
FIGURE 2 | Mir-451 comes from a link RNA (not shown in graph).
Mir-451 has 10 known targets (green). These targets are part of a number of
reactome pathways (blue). The number in the blue nodes can be used to
access the associated reactome pathway, and Table S3 in Supplementary
Material provides further information for clarity. Size of blue nodes reflects
the number of mir-885 targets it contains. Edges ending in circles (gray)
indicate a part of relationship (e.g., FBP1 is a part of the “glycogen storage
diseases” pathway, which has the reactome accession number 3229121).
Edges ending in straight lines (red) indicate inhibition of the target (e.g.,
mir-451 inhibits AKT1).
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FIGURE 3 | Mir-885 comes from an intron in ATP2B2 (both red). Mir-885
has two known targets (green). These targets are part of a number of
reactome pathways (blue). The Number in the blue nodes can be used to
access the associated reactome pathway and Table S2 in Supplementary
Material provides further information for clarity. Size of blue nodes reflects
the number of mir-885 targets it contains. Edges ending in circles (gray)
indicate a part of relationship (e.g., CDK2 is a part of the “Activation of the
pre-replicative complex” pathway, which has the reactome accession number
68962). Edges ending in straight lines (red) indicate inhibition of the target
(e.g., mir-885 inhibits MCM5).
a lincRNA (ENSG00000264066), miR-885 is located in an intron
of plasma membrane calcium-transporting ATPase 2 (ATP2B2).
Overall, miR-451 has 10 targets, which are involved in 154 dis-
tinct reactome pathways (Figure 2; Table S2 in Supplementary
Material). miR-885-5p has two confirmed targets, which are
involved in 50 distinct reactome pathways (Figure 3; Table S3 in
Supplementary Material).
PROFILING mRNA EXPRESSION CHANGES FOLLOWING EPO
TREATMENT
We performed high-density oligonucleotide microarray analyses
(n= 3) to determine the changes in gene expression induced by
EPO in SH-SY5Y cells. Our data demonstrate EPO treatment
upregulated 51 genes and downregulated 23 genes considering
a fold change >1.5 (p value <0.05) (Tables 2 and 3).
qPCR ARRAY
We used qPCR array to validate gene expression changes of 26
genes. Aliquots of the same RNA sample were used for all the exper-
iments in both the microarray and qPCR array measurements.
Figure 4 shows that the qPCR findings were highly correlated with
the microarray data (Pearson’s R= 0.95, p= 0.000). Data from the
mRNA microarray experiment are shown in Tables 2 and 3 and
qPCR results are shown in Tables S4 and S5 in Supplementary
Material.
qPCR ANALYSIS OF SELECTED TARGET GENES AT DIFFERENT TIME
POINT OF EPO TREATMENT
We examined the gene expression levels of these miRNA target
genes at different time points after EPO treatment. We found
that EPO upregulates matrix metallo peptidase 9 (MMP9), B-
celllymphoma 2 (BCL2), EPOR, and Galanin (GAL) expression
at 24 and 48 h, vascular endothelial growth factor A (VEGFA),
mini chromosome maintenance complex 5 (MCM5) at 48 h, and
cyclin-dependent kinase 2 (CDK2) expression at 3 h (Table 4;
Figure 5).
UPREGULATION OF miR-451 AND miR-885-5p EXPRESSION CAN INHIBIT
THEIR TARGET GENE EXPRESSION
To determine whether differentially expressed miRNA can regulate
their target genes’ expression in SH-SY5Y cells, we investigated the
modulation of MMP9, BCL2, VEGFA, EPOR, MCM5, and GAL
mRNA levels in cells transfected with mimics of miR-451 and
miR-885-5p by qPCR. The result of real-time qPCR revealed that
miR-451 and miR-885-5p mimics can significantly decrease the
basal expression of MMP9, BCL2, VEGFA, EPOR, MCM5, and
GAL, suggesting that mimics efficiently introduced into the cells
and decreased the expression of their target genes (Figure 6A).
We found that cells transiently transfected with miR-451 and
miR-885-5p mimics had significantly reduced EPO-induced target
genes expression at 24 h (MMP9, BCL2) and at 48 h (MMP9, BCL2,
VEGFA, EPOR, MCM5, and GAL) (Figures 6B,C).
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Table 2 | Upregulated genes following 48 h EPO treatment of SH-SY5Y cells.
Genes Description Fold
change
p value
DLK1 Delta, drosophila, homolog like 1 2.645 0.0017
GAL Galanin 2.426 0.0003
CABP7 Calcium-binding protein 2.364 4.6E-05
LOC440063 Cyclophilin A pseudogene 2.274 0.04
BHLHB2 Basic helix loop helix domain containing protein class B2 2.134 0.00025
IGF2 Insulin like growth factor 2 2.105 0.00057
GNAS Guanine nucleotide binding protein 2.001 0.00031
TRK1 Transfer RNA Lysine 1 1.836 0.030
NELL2 NEL like 2 1.828 0.0031
C20ORF46 Transmembrane protein 1.813 0.00024
IGSF21 Immunoglobulin super family member 21 1.809 0.0032
RAB6B Member RAS oncogene family 1.795 0.00022
GALNTL4 UDP-N -acetyl-alpha-D-galactosamine:polypeptide; N -acetylgalactosaminyltransferase-like 4 1.788 0.00024
OLFM1 Olfactomedin 1- neuroblastoma protein 1.78 0.0020
C20ORF160 Chromosome 20 open reading frame 160 1.78 0.0036
SOBP Sine Oculus binding protein homolog drosophila 1.766 0.0026
NR2F2 Nuclear receptor sub-family 2 1.757 0.0036
SGPP2 Sphingosine 1 phosphate phosphatase 2 1.756 0.014
C3ORF32 Chromosome 3 open reading frame 32 1.749 0.00046
SUSD2 Sushi domain containing 2 1.728 0.0028
C2CD4B C2 Calcium dependent domain containing protein 4B 1.727 0.011
TSPAN7 Tetraspanin 7 1.691 0.0008
VEGFA Vascular endothelial growth factor A 1.69 0.0043
SORBS2 Sorbin and SH3 domain containing 2 1.686 0.00091
CNTNAP4 Contactin associated protein 4 1.662 0.00014
LOC100132291 Ribosomal protein S27 pseudogene 29 1.656 0.034
CDKN1C Cyclin-dependent kinase inhibitor 1C 1.651 0.007
LOC391019 Ribosomal protein L29 pseudogene 6 1.643 0.023
LOC729086 Vesicular overexpressed in cancer, prosurvival protein 1 pseudogene 1.639 0.029
BOLA2 Bol A2 homolog (E. coli ) 1.634 0.0027
SH2D3C SH domain containing protein 3C 1.617 0.0017
FLJ43681 Ribosomal protein L23a pseudogene 1.608 0.024
CYB5A Cytochrome b5 type A (microosomal) 1.606 0.002
LOC442232 Ribosomal protein L17 pseudogene 25 1.6 0.017
TSPAN4 Tetraspanin 4 1.59 0.008
HES4 Hairy enhancer of split. drosophila homolog of 4 1.583 0.013
LOC728820 Ribosomal protein L29 pseudogene 15 1.582 0.013
LOC92755 Tubulin beta pseudogene 1 1.58 0.0063
CXCR4 Chemokine CXC motif receptor 4 1.579 0.00029
HBQ1 Hemoglobin theta 1 1.575 0.017
LOC100128060 Ribosomal protein S7 pseudogene 10 1.562 0.029
LOC731640 Ribosomal protein L21 pseudogene 97 1.553 0.016
AQP10 Aquaporin 10 1.549 0.0021
RPL14 Ribosomal protein L14 1.543 0.033
SYP Synaptophysin 1.541 0.0009
LOC651453 Ribosomal protein L36 pseudogene 14 1.53 0.017
MCM2 Minichromosome maintenance complex component 2 1.528 0.004
SLC7A14 Solute carrier family 7 member 14 1.516 0.028
INS-IGF2 INS-IGF2 readthrough 1.513 0.010
HCN3 Hyperpolarization activated cyclic nucleotide gated potassium channel 3 1.512 0.0016
GALNTL1 UDP-N -acetyl-alpha-D-galactosamine:polypeptide; N -acetylgalactosaminyltransferase-like 1 1.512 0.008
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Table 3 | Downregulated genes following 48 h EPO treatment of
SH-SY5Y cells.
Genes Description Fold
change
p value
FOS FBJ murine osteosarcoma viral
oncogene homolog
0.172 7.6E-03
TAGLN Transgelin 0.227 6.3E-04
IL13RA2 Interleukin 13 receptor, alpha 2 0.344 1.9E-03
FOSB FBJ murine osteosarcoma viral
oncogene homolog B
0.344 7.2E-02
PRSS23 Protease, serine, 23 0.362 3.5E-03
MME Membrane metallo-endopeptidase 0.382 5.5E-04
LRRC17 Leucine rich repeat containing 17 0.41 6.3E-03
S100A10 S100 calcium-binding protein A10 0.425 2.9E-04
TSPAN8 Tetraspanin 8 0.439 6.0E-03
EGR1 Early growth response 1 0.443 5.2E-02
TP53I3 Tumor protein p53 inducible protein 3 0.446 3.0E-04
GPNMB Glycoprotein (transmembrane) nmb 0.448 6.3E-03
SPARC Secreted protein, acidic, cysteine-rich 0.455 8.9E-05
COL3A1 Collagen, type III, alpha 1 0.457 1.2E-03
OLFML3 Olfactomedin-like 3 0.461 2.8E-03
AHNAK AHNAK nucleoprotein 0.467 1.1E-04
IFITM3 interferon induced transmembrane
protein 3
0.468 1.7E-04
HTRA1 HtrA serine peptidase 1 0.476 1.7E-03
MATN2 Matrilin 2 0.476 1.7E-02
COL5A2 Collagen, type V, alpha 0.489 4.5E-03
IFITM2 Interferon induced transmembrane
protein 2
0.491 8.8E-04
MGP Matrix Gla Protein 0.492 4.1E-04
S100A13 S100 calcium-binding protein A13 0.495 7.5E-02
DOWNREGULATION OF miR-451 AND miR-885-5p CONTRIBUTES TO THE
NEUROPROTECTIVE EFFECTS OF EPO
To evaluate the role of miR-451 and miR-885-5p in the protec-
tive effect of EPO, SH-SY5Y cells were transfected with mimics
to investigate the effect of over-expression of these miRNAs. The
EPO responsiveness in respect to cell death induced by CoCl2
was examined with the WST-8 assay. Cell viability significantly
decreased with CoCl2, which can be reversed by EPO pretreat-
ment. After upregulation of miR-451 and miR-885-5p levels with
mimics, the cell viability levels in EPO-treated cells did not reach
the levels in the negative control mimic group (Figures 7A–C).
This finding suggests that the protective effect of EPO was in part
dependent on the expression levels of miR-451 and miR-885-5p.
OVER-EXPRESSION OF miR-451 AND miR-885-5p CAN REVERSE
ANTI-APOPTOTIC EFFECT OF EPO
Previous findings indicated that EPO inhibits apoptosis induced
by STS. Here, we investigated the effects of EPO on apoptosis of
SH-SY5Y cells following an increase in miR-451 and miR-885-5p
levels upon transfection with mimics.
Cells were transfected with mimics to simulate over-expression
of miR-451 and miR-885-5p. As expected, EPO effects on miR-451
and miR-885-5p expression were diminished in cells transfected
with mimics (Figures 8A,B). Consequently, EPO-mediated anti-
apoptotic effect was significantly reduced in the mimics trans-
fected cells as compared with cells that were transfected with
control mimics. This indicates the importance of miR-451 and
miR-885-5p in mediating the anti-apoptotic effect of EPO. We
also found that there is an impact of miR-451 and miR-885-5p
on EPO’s anti-apoptotic effects in response to CoCl2 induced
apoptosis (Figure 8C).
OVER-EXPRESSION OF miR-451 AND miR-885-5p CAN REVERSE THE
ANTI-OXIDANT EFFECT OF EPO
In order to evaluate the role of miR-451 and miR-885-5p for the
anti-oxidant effect of EPO, we investigated the effects of EPO
on ROS production induced by CoCl2 in SH-SY5Y cells after
FIGURE 4 | qRT-PCR array validation of the microarray data for the selected genes. The RT-PCR data were normalized to the housekeeping gene β-actin.
Pearson’s coefficient, r =0.95, p=0.000.
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transfection with mimics. As shown in Figure 8D, the anti-oxidant
effect of EPO was attenuated by mimics of miR-451 and miR-
885-5p. Our results indicate the importance of miR-451 and
miR-885-5p in mediating the anti-oxidant effect of EPO.
UPREGULATION OF miR-451 AND miR-885-5p AFFECTS PROLIFERATION
OF SH-SY5Y CELLS ENHANCED BY EPO
Cell proliferation was evaluated after transfection with mim-
ics to determine the impact of miR-451 and miR-885-5p on
the proliferative effect of EPO. According to our results, EPO
increases proliferation of SH-SY5Y cells at 24 and 48 h after treat-
ment (Figures 9A,B). We found that cells transiently transfected
with miR-451 and miR-885-5p mimics had significantly reduced
proliferation as compared with cells transfected with control
mimics.
DOWNREGULATION OF miR-451 AND miR-885-5p CONTRIBUTES TO THE
NEURONAL MIGRATORY EFFECT OF EPO
We further investigated the role of miR-451 and miR-885-5p on
the migratory effects of EPO. SH-SY5Y cells were transfected with
FIGURE 5 |Time-dependent CDK2 gene expression changes following
EPO treatment in SH-SY5Y cells. Cells were treated with 1 U/ml EPO
during 0–24 h time intervals. Expression levels of CDK2 were quantified by
qRT-PCR. CDK2; cell cycle dependent kinase 2. The data are presented as
mean±SE, n=5 (*p<0.05).
miR-451 and miR-885-5p mimics or control miRNAs for 48 h
and then EPO responsiveness on cell migration was examined
with scratch assay. We found that the EPO-mediated migratory
effect was significantly reduced in the mimics transfected cells as
compared with cells that were transfected with control mimics
(Figures 10A,B).
EFFECTS OF miR-451 AND miR-885-5p UPREGULATION ON
EPO-MEDIATED NEURITE OUTGROWTH AND NEURITE LENGTH IN
SH-SY5Y CELLS
To investigate the role of miR-451 and miR-885-5p upregulation
on EPO-mediated neurite outgrowth in SH-SY5Y cells, we used
mimics to simulate over-expression of miR-451 and miR-885-
5p. EPO significantly increased neurite outgrowth to 69.5± 5.3%
relative to controls and the increase remained unchanged in nega-
tive control mimics transfected cells (73.4± 3.9%). However, the
increase due to EPO treatment in the percentage of neurite-bearing
cells was significantly attenuated in those cells transfected with
mimics (Figures 11A,B).
Similar results were obtained for neurite length analysis. EPO
increases neurite length of SH-SY5Y cells after 24 h treatment
(Figures 11C,D). We found that cells transiently transfected with
miR-451 and miR-885-5p mimics had significantly reduced neu-
rite length compared with that of cells transfected with control
mimics. These results show that the miR-451 and miR-885-5p are
involved in the induction of neurite outgrowth in SH-SY5Ycells.
DISCUSSION
Erythropoietin is a well-known cytokine growth factor, which
exerts pleiotropic effects including neurotrophic, neuroprotective,
anti-apoptotic, anti-oxidative, and immune-modulatory activ-
ities. For instance, EPO inhibits pro-inflammatory cytokine
release and T cell responses in experimental autoimmune
encephalomyelitis (EAE) (26, 27). Proposed mechanisms of neu-
roprotective effects of EPO include gene expression regulation
at the post-transcriptional level including alteration of miRNA
expression. Here, we analyzed the effect of EPO on miRNA
expression in SH-SY5Y neuronal-like cells. MicroRNA microarray
experiments showed that miR-451 and miR-885-5p were down-
regulated by 24 h EPO treatment. Real-time qPCR studies verified
the miRNA microarray results.
In this in vitro study, we chose SH-SY5Y human neuroblastoma
cells as cell culture model because of their high transfection effi-
ciency. SH-SY5Y cells express EPOR and other tissue-protective
Table 4 | Selected target mRNA expression changes of miR-451 and miR-885-5p in EPO-treated SH-SY5Y cells.
MicroRNA Target mRNA 24 h EPO treatment 48 h EPO treatment
Fold change pValue Fold change pValue
miR-451 BCL2 2.19 0.014 2.52 0.014
VEGFA 1.01 0.917 1.59 0.014
EPOR 0.97 0.917 1.48 0.009
miR-885-5p MCM5 1.02 0.917 1.56 0.009
GAL 0.98 0.806 1.73 0.014
Both (miR-451 and miR-885-5p) MMP9 1.44 0.028 2.10 0.009
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FIGURE 6 | miR-451 and miR-885-5p significantly downregulate expression of target genes in SH-SY5Y cells. qRT-PCR was performed to determine the
mRNA levels of target genes after transfection of SH-SY5Y cells with miR-451, miR-885-5p mimics, and negative control (NC) miRNAs without EPO treatment
(A), with 24 h EPO treatment (B) and 48 h EPO treatment (C). Control: cells without any transfection. The data are presented as mean±SE, n=5 (*p<0.05).
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FIGURE 7 | miR-451 and miR-885-5p may mediate the neuroprotective
effect of EPO. Transfected and non-transfected cells were treated with
EPO and/or CoCl2. (A) Cell viability was analyzed by WST-8 assay,
(B) representative phase-contrast microcopy images of SH-SY5Y cells, and
(C) representative light microscopy images showing trypan blue stained
dead cells. Over-expression of miR-451 and miR-885-5p reverse the
neuroprotective effect of EPO induced by CoCl2. CoCl2; cobalt chloride,
EPO; erythropoietin. The data are presented as mean±SE, n=5
(*p<0.05 compared to control and #p<0.05 compared to CoCl2 treated
cells).
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FIGURE 8 | Anti-apoptotic and anti-oxidant effects of EPO in SH-SY5Y
cells may be regulated by miR-451 and miR-885-5p. Transfected and
non-transfected cells were treated by staurosporine (STS) (25 nM) and
1 U/ml EPO. (A) DNA fragmentation was evaluated by cell death ELISA
assay. (B) Apoptotic phosphatidylserine (PS) positive cells were stained by
Annexin-V-FITC dye and visualized using immunofluorescence microscopy.
Cells were also treated with CoCl2 (250µM) and 1 U/ml EPO (C) and DNA
fragmentation was analyzed by cell death ELISA assay. Transfection of
miR-451 and miR-885-5p mimics reduced the anti-apoptotic effect of EPO
in both STS and CoCl2 induced apoptosis. (D) Intracellular ROS production
was quantified by using the CM-H2DCFDA method. Over-expression of
miR-451 and miR-885-5p reversed anti-oxidant effect of EPO induced by
CoCl2. STS; staurosporin, EPO; erythropoietin, CM-H2DCFDA;
2′,7′-dichlorodihydrofluorescein, acetyl ester. The data are presented as
mean±SE, n=5 [*p<0.05 compared to control and #p<0.05 compared
to toxic agents (STS or CoCl2) treated cells].
EPO receptors such as CD131 (26). In addition, cellular and mol-
ecular actions of EPO have been widely studied in this model such
as proliferative, anti-apoptotic, anti-oxidant, anti-inflammatory,
and neurite outgrowth promoting effects (28–30).
In this study, we demonstrated, for the first time, that select
miRNAs are regulated by EPO in neuronal SH-SY5Y cells. Previ-
ously, only one study evaluated the effect of EPO on the miRNA
expression profile in murine erythroid cells (18). In that study,
miR-210, miR-188, and miR-362 were significantly elevated with
stimulation of EPO. miR-210 has been demonstrated to be a neu-
roprotective miRNA against oxygen-glucose deprivation in PC12
cells (31). This miRNA is well known to stimulate angiogenesis and
neurogenesis (32). As activity-regulated miRNA, miR-188 shows
neurotrophic effects in rat hippocampal neurons (33). We could
not detect any change in miR-210 and miR-188 expression profiles
in EPO-treated SH-SY5Y cells. This discrepancy may be due to
species and cell type differences. Another plausible explanation
could be the use of different exposure duration and dose of EPO.
In our hand, EPO dose of one unit did not show any change
in the expression of miR-210 in time course qPCR experiments
(3–48 h, data not shown). Our ongoing studies, especially, focus
on whether miR-210 mediates the promoting effect of EPO on
angiogenesis and neurogenesis in neural progenitor and cerebral
endothelial cells.
We performed mRNA microarray analysis to evaluate mRNA
changes in EPO-treated SH-SY5Y cells. EPO treatment in
SH-SY5Y neuronal cells upregulated 51 genes and downregu-
lated 23 genes. EPO caused changes in the expression of genes
involved in cell proliferation, cell survival, and cell differentiation.
There are some contradictory and similar results as compared
Frontiers in Immunology | Inflammation September 2014 | Volume 5 | Article 475 | 12
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alural et al. MicroRNA-mediated erythropoietin cytoprotection
FIGURE 9 | Upregulation of miR-451 and miR-885-5p reduces
proliferation of SH-SY5Y cells enhanced by EPO. In miRNA mimic
transfected and non-transfected cells, cell proliferation was observed by
counting cells using phase-contrast microscopy following either 24 or 48 h
EPO treatment. (A) Cell counts and (B) phase-contrast microscopy images.
Transfection of miR-451 and miR-885-5p mimics reduces the proliferative
effect of EPO. EPO; erythropoietin. The data are presented as mean±SE,
n=5 (*p<0.05).
with previous EPO mRNA array studies in the literature. The
discrepancies that discussed above in detail may be due to tech-
nical limitations that also interfere with miRNA expression pro-
filing results. Although the comparison of in vitro and in vivo
findings may be somewhat problematic, the results of a previ-
ous in vivo study by Anderson et al. are comparable with our
transcriptome profiling (14). They found that chemokine (C–
X–C Motif) receptor 4 (CXCR4), Gal, and IGF2 upregulated at
different time points, 24 h–7 days, in the brains of EPO-treated
rats. In another experimental rodent infarct model, CXCR4 was
found significantly upregulated in EPO-treated rats (34). Although
VEGFA upregulation has not been reported in previous mRNA
array studies, we found that EPO increased VEGFA expression by
qPCR. As a neuroprotectant, neurotrophic, and angiogenic mol-
ecule, VEGFA may mediate the effects of EPO in the nervous
system (35). Conversely, EPO-mediated VEGFA gene regulation
may proceed via downregulation of miR-451, as revealed by our
mimic transfection study. Gal, which is a target of miR-885-5p has
neuroprotective, neurotrophic, and immunomodulatory effects
(36). Future studies using Gal siRNA or GAL receptor block-
ers may delineate the Gal gene regulation mechanisms induced
by EPO. Using cultured rat PC12 cells or rat B104 neuroblas-
toma cells, other groups found upregulation in anti-apoptotic
genes, BCLXL and BCL2, respectively (9, 37). We also found an
increase in BCL2 expression by qPCR. We also confirmed the
finding that EPO-mediated EPOR expression in SH-SY5Y cells
(28, 38). In addition, we also studied cell cycle regulating genes,
MCM5 and CDK2 that are targets of miR-885-5p (39). EPO sig-
nificantly increased their expression and mimics of miR-885-5p
reversed the resulting effect, suggesting that EPO regulates cell
cycle genes in an miRNA-dependent manner. As validated tar-
gets of EPO downregulated miRNAs (miR-451 and miR-885-5p),
MMP9 may mediate neuronal migratory and angiogenic effects of
EPO.
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FIGURE 10 | EPO induces migration in SH-SY5Y cells, which can be
reversed by mir-451 and mir-885-5p. Transfected and non-transfected
cells were treated with 1 U/ml EPO and migration assay was conducted
for either condition. (A) Cells were counted by using ImageJ 1.42
(http://imagej.nih.gov/ij/). (B) Representative images of migrated SH-SY5Y
cells. Over-expression of miR-451 and miR-885-5p reverse the migratory
effect of EPO. EPO, erythropoietin. The data are presented as mean±SE,
n=3 (*p<0.05).
In the current study, we choose a single time point for mRNA
assay. In the literature, some EPO-induced genes such as BCLXL
are upregulated as early as at 3 h and the expression of others
peaked at a very late time point such as 7 days (MMP9) (9, 14).
Thus, we might fail to detect possible expression changes of some
EPO-regulated genes such as CDK2. As a powerful technique and
gold standard method, qPCR may detect tiny expression changes
as revealed in our study. In contrast to mRNA array, qPCR showed
upregulation of some EPO-regulated genes (BCL2, EPOR, and
MCM5) at 48 h.
We found some genes whose expressions are upreg-
ulated by EPO in our mRNA microarray study: IGF2
(neuroprotection), CXCR4 (neural migration, immunomodula-
tion, neuroprotection), and synaptophysin (synaptogenesis). Since
differentially regulated miRNAs, miR-451 and miR-885-5p, did
not target those genes, we did not focus on miRNA-mediated reg-
ulation of them in this study. Future studies may provide insight
on the roles of these miRNA–mRNA interactions on the effects
of EPO. As shown in non-neuronal cells, miRNAs may be both
regulators and mediators of EPO’s action. For instance, miR-125b
downregulates EPO and EPOR expression in breast MCF7 cancer
cell lines (40). In another study, brain enriched miRNA, miR-132
downregulated the expression of EPO via the inhibition of Nrf2
transcription factor in rat epithelial cells (41).
Frontiers in Immunology | Inflammation September 2014 | Volume 5 | Article 475 | 14
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alural et al. MicroRNA-mediated erythropoietin cytoprotection
FIGURE 11 | EPO may enhance neurite outgrowth and length via
regulation of miR-451 and miR-885-5p. Transfected and non-transfected
cells were treated with 1 U/ml EPO. (A) Neurite cell number was counted
using ImageJ 1.42 (http://imagej.nih.gov/ij/). Randomly selected fields in
microscopic analysis with an average of 35 cells per field were analyzed.
(B) Representative phase-contrast microscopy images are shown in order
to indicate the increased neurite numbers induced by EPO and reversed
by the transfection of mimics of miR-451 and miR-885-5p. (C) The average
maximal neurite length for both, the transfected and non-transfected cells
were analyzed by ImageJ 1.42 (http://imagej.nih.gov/ij/). At least 30
neurites per condition were measured. (D) Neurite length distribution.
Arrowheads indicate the neurites arising from cells. Scale bar, 100µm.
EPO, erythropoietin. The data are presented as mean±SE, n=5
(*p<0.05).
In this study, we did not focus on the possible mechanism of
EPO-mediated miRNA regulation. EPO modulates various signal-
ing pathways and transcription factors and may use these mecha-
nisms to regulate miRNA expression (8). Another interesting point
is the differences between EPO and its variant carbamylated EPO
(42). First, the effects of EPO variants on miRNA expression profil-
ing should be studied. Then supporting functional studies should
be performed using mRNAs mimics and antagomirs. EPO exerts
similar cytoprotective effects in non-neuronal cells of nervous
system. Thus, the results of miRNA expression profiling studies
using cultured astrocytes, microglia, oligodendroglia, and cerebral
endothelial cells will also be informative. Here, the expression of
pri- and pre-forms of miRNAs was not studied and only mature
forms were evaluated. Such studies will give more information
on the molecular level(s) in which EPO modulates specific miR-
NAs. Another issue that should be addressed in future studies
is the detection of exosomal miRNAs, especially miR-451, in the
EPO-treated supernatant of cultured cells (43, 44).
The extrapolation of in vitro results to in vivo status is not with-
out limitation. Thus, experimental animal studies should also be
designed and performed using mimics or antagomirs of selected
miRNAs. Complementary behavioral, electrophysiological, and
bioinformatics analyses are also a mandatory part of in vivo studies
combined miRNAs in situ hybridization/immunohistochemical
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analyses or sophisticated techniques such as laser captured
microdissection microscopy will help to reveal miRNAs expression
changes at the cellular level.
In conclusion, to the best of our knowledge, this is the first inte-
grative miRNA–mRNA study using EPO. Such studies will uncover
the mechanism of cellular and molecular actions of EPO at differ-
ent regulation steps. Future studies focusing on miRNA-mediated
mechanisms may provide novel insight on how biological effects
of EPO are modulated.
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